Positioning of apremilast in treatment of Behçet’s disease

References

• Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med. 1999;341(17):1284–91.
   PubMed Web of Science ®Google Scholar
• Yazici H, Seyahi E, Hatemi G, Yazici Y. Behcet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14(2):107–19.
   PubMed Web of Science ®Google Scholar
• Greco A, De Virgilio A, Ralli M, Ciofalo A, Mancini P, Attanasio G, et al. Behcet's disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018;17(6):567–75.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808–18.
   PubMed Web of Science ®Google Scholar
• Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behcet disease: evolution of clinical manifestations. Medicine (Baltimore). 2011;90(2):125–32.
   PubMed Web of Science ®Google Scholar
• Leccese P, Ozguler Y, Christensen R, Esatoglu SN, Bang D, Bodaghi B, et al. Management of skin, mucosa and joint involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations for the management of Behçet’s syndrome. Semin Arthritis Rheum. 2019;48(4):752–62.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, et al. Apremilast for Behçet’s syndrome — a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510–8.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, et al. Trial of apremilast for oral ulcers in Behcet's syndrome. N Engl J Med. 2019;381(20):1918–28.
   PubMed Web of Science ®Google Scholar
• De Luca G, Cariddi A, Campochiaro C, Vanni D, Boffini N, Tomelleri A, et al. Efficacy and safety of apremilast for Behcet's syndrome: a real-life single-centre Italian experience. Rheumatology (Oxford). 2019. doi: 10.1093/rheumatology/kez267. [Epub ahead of print]
   PubMedGoogle Scholar
• Lopalco G, Venerito V, Leccese P, Emmi G, Cantarini L, Lascaro N, et al. Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet’s disease. Ann Rheum Dis. 2019;78(12):1736.
   PubMed Web of Science ®Google Scholar
• Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014;13(4):290–314.
   PubMed Web of Science ®Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–90.
   PubMed Web of Science ®Google Scholar
• Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048
   PubMed Web of Science ®Google Scholar
• Schafer PH, Truzzi F, Parton A, Wu L, Kosek J, Zhang L-H, et al. Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex. Cell Signal. 2016;28(7):753–63.
   PubMed Web of Science ®Google Scholar
• Spadaccini M, D'Alessio S, Peyrin-Biroulet L, Danese S. PDE4 inhibition and inflammatory bowel disease: a novel therapeutic avenue. Int J Mol Sci 2017;18(6):E1276.
   PubMed Web of Science ®Google Scholar
• Reed M, Crosbie D. Apremilast in the treatment of psoriatic arthritis: a perspective review. Ther Adv Musculoskelet Dis. 2017;9(2):45–53.
   PubMed Web of Science ®Google Scholar
• Bos JL. Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci. 2006;31(12):680–6.
   PubMed Web of Science ®Google Scholar
• Mavropoulos A, Zafiriou E, Simopoulou T, Brotis AG, Liaskos C, Roussaki-Schulze A, et al. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis. Rheumatology. 2019. doi: 10.1093/rheumatology/kez204. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kragstrup TW, Adams M, Lomholt S, Nielsen MA, Heftdal LD, Schafer P, et al. IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis. Ther Adv Musculoskelet Dis. 2019;11:1759720x19828669.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Aydin SZ, Gul A, Mahr A, Direskeneli H. 'MHC-I-opathy'-unified concept for spondyloarthritis and Behcet disease. Nat Rev Rheumatol. 2015;11(12):731–40.
   PubMed Web of Science ®Google Scholar
• Chandran V. The genetics of psoriasis and psoriatic arthritis. Clinic Rev Allerg Immunol. 2013;44(2):149–56.
   PubMed Web of Science ®Google Scholar
• Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73.
   PubMed Web of Science ®Google Scholar
• Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet. 2010;42(8):703–6.
   PubMed Web of Science ®Google Scholar
• Strange A, Capon F, Spencer CCA, Knight J, Weale ME, Allen MH, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42(11):985–90.
   PubMed Web of Science ®Google Scholar
• Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet. 2013;45(2):202–7.
   PubMed Web of Science ®Google Scholar
• Kirino Y, Nakajima H. Clinical and genetic aspects of Behçet's disease in Japan. Intern Med. 2019;58(9):1199–207.
   PubMed Web of Science ®Google Scholar
• Kirino M, Kirino Y, Takeno M, Nagashima Y, Takahashi K, Kobayashi M, et al. Heme oxygenase 1 attenuates the development of atopic dermatitis-like lesions in mice: implications for human disease. J Allergy Clin Immunol. 2008;122(2):290–7, 290.e1–8.
   PubMed Web of Science ®Google Scholar
• Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet. 2010;42(8):698–702.
   PubMed Web of Science ®Google Scholar
• Kirino Y, Zhou Q, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease. Proc Natl Acad Sci. 2013;110(20):8134–9.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behçet's disease: a comprehensive review. J Autoimmun. 2015;64:137–48.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Ombrello MJ, Kirino Y, Erer B, Tugal-Tutkun I, Seyahi E, et al. A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet's disease in HLA-B*51 carriers. Ann Rheum Dis. 2016;75(12):2208–11.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Mizuki N, Meguro A, Ombrello MJ, Kirino Y, Satorius C, et al. Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility. Nat Genet. 2017;49(3):438–43.
   PubMed Web of Science ®Google Scholar
• Kirino Y, Takeno M, Watanabe R, Murakami S, Kobayashi M, Ideguchi H, et al. Association of reduced heme oxygenase-1 with excessive Toll-like receptor 4 expression in peripheral blood mononuclear cells in Behçet's disease. Arthritis Res Ther. 2008;10(1):R16.
   PubMed Web of Science ®Google Scholar
• Furst DE, Belasco J, Louie JS. Genetic and inflammatory factors associated with psoriatic arthritis: relevance to diagnosis and management. Clin Immunol. 2019;202:59–75.
   PubMed Web of Science ®Google Scholar
• Criteria for diagnosis of Behcet's disease. International study group for Behcet's Disease. Lancet 1990;335(8697):1078–80.
   PubMed Web of Science ®Google Scholar
• Dudding T, Haworth S, Lind PA, Sathirapongsasuti JF, Tung JY, Mitchell R, et al. Genome wide analysis for mouth ulcers identifies associations at immune regulatory loci. Nat Commun. 2019;10(1):1052.
   PubMedGoogle Scholar
• Coates LC, Murphy R, Helliwell PS. New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. Br J Dermatol. 2016;174(6):1174–8.
   PubMed Web of Science ®Google Scholar
• Vossen A, Van Doorn MBA, Van Der Zee HH, Prens EP. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. 2019;80(1):80–8.
   PubMed Web of Science ®Google Scholar
• Narang T, Kaushik A, Dogra S. Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases. Br J Dermatol. 2019. doi: 10.1111/bjd.18233. [Epub ahead of print]
   Web of Science ®Google Scholar
• Pearse DD, Hughes ZA. PDE4B as a microglia target to reduce neuroinflammation. Glia 2016;64(10):1698–709.
   PubMed Web of Science ®Google Scholar